Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056247 · ClinicalTrials.gov registry record
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
A clinical trial of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer, sponsored by OncoHost.
- Active
- Registry status
- 10,000
- Enrollment target
- 20
- Study locations
NCT04056247: Active study of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer, sponsored by OncoHost.
NCT04056247 is a study of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer that is active but no longer recruiting, run by OncoHost. The registered enrollment target is 10,000 participants, above the 255-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (3822% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04056247, a study of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer, is active but no longer recruiting, sponsored by OncoHost.
- ACTIVE NOT RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
Primary Outcome
Biological features are analyzed in biological samples taken from the patients as part of the study
Conditions Studied
Interventions
- OTHER Plasma sample collection
Study Locations (20)
Other
- Asklepois - Gauting
- Thoraxklinik Heidelberg gGmbH - Heidelberg
- Haemek Medical Center - Afula
- Barzilai Medical Center - Ashkelon
- Soroka Medical Center - Beersheba
- Shamir Medical Center - Be’er Ya‘aqov
- Bnai Zion Medical Center - Haifa
- Rambam Medical Center - Haifa
Florida
- Mayo Clinic - Jacksonville
- University of Miami - Miami
- Florida Cancer Specialist and Research Institute - Orlando
- Protean Biodiagnosics - Orlando
Texas
- Michael E. Debakey VA Medical Center - Houston
- 151-Christus Health St. Michael - Texarkana
Alabama
- Birmingham VAHCS - Birmingham
Illinois
- Northwest Community Healthcare - Rolling Meadows
Iowa
- Helen Nassif Community Cancer Center - Cedar Rapids
New Jersey
- Rutgers Cancer Institute - New Brunswick
New York
- Roswell Park - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2029-10-01 |
What the registry record for NCT04056247 still lists
NCT04056247 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 255-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (3822% higher).
The record links to 5 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Plasma sample collection is the first listed.
NCT04056247 names 20 study sites across 9 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04056247 about?
NCT04056247 is a clinical study titled "Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments". The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatme...
What is the current status of trial NCT04056247?
This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2019-10-01. Estimated completion is 2029-10-01.
What conditions does trial NCT04056247 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma.
What interventions are being tested in trial NCT04056247?
The interventions under investigation include: Plasma sample collection (OTHER).
Who is sponsoring clinical trial NCT04056247?
This trial is sponsored by OncoHost, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04056247 being conducted?
This trial has 20 study locations across Alabama, Florida, Illinois, Iowa, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04056247's enrollment target sits among peer trials
10,000 1st of 23 higher than 23 of 23 other Stage IV Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI